One of the most significant differences in prenatal care for women over 35 compared to younger age groups is the expanded landscape of genetic testing options available—and the conversations that come with them. For many women, navigating this landscape for the first time during a pregnancy can feel overwhelming, particularly when balancing physical symptoms, emotional adjustment, and medical appointments in the first trimester.
Understanding what prenatal genetic testing involves, what it can and cannot tell you, and how the options differ from one another can help make those conversations with your healthcare provider more grounded and productive. This overview is intended to provide informational context, not to recommend any specific course of action—those decisions are deeply personal and should be made in close partnership with your medical team.
After age 35, the statistical likelihood of certain chromosomal conditions—including Down syndrome (trisomy 21), trisomy 18, and trisomy 13—increases with advancing maternal age. This is the primary reason additional genetic testing conversations are recommended for this age group. However, it’s equally important to note that the vast majority of pregnancies after 35 involve chromosomally typical babies, and testing results are ultimately probabilities and possibilities, not certainties.
What Research and Guidelines Say About Testing After 35
According to the American College of Obstetricians and Gynecologists (ACOG), prenatal genetic screening and diagnostic testing should be offered to all pregnant women regardless of age, with the understanding that the decision to pursue testing is a personal one. For women over 35, the conversations about these options tend to be more prominent given age-related changes in statistical risk.
The key distinction in prenatal genetic testing is between screening tests and diagnostic tests, and understanding this difference is foundational to making informed decisions.
Screening Tests: What They Involve
Screening tests assess the statistical likelihood that a pregnancy may be affected by certain chromosomal conditions. They do not provide definitive diagnoses. The most commonly discussed screening options in the first trimester include:
Cell-Free DNA Testing (NIPT)
Non-invasive prenatal testing (NIPT) analyzes fragments of placental DNA circulating in the mother’s blood. It is typically offered after 10 weeks of pregnancy and screens for the most common chromosomal conditions. NIPT has relatively high sensitivity and specificity for the conditions it screens for, but it is still a screening test—positive results require confirmation through diagnostic testing, and false positives do occur.
First Trimester Combined Screening
This approach combines a blood test measuring pregnancy hormones (PAPP-A and hCG) with an ultrasound assessment of the nuchal translucency (a measurement at the back of the baby’s neck) to generate a risk estimate. It is typically performed between 11 and 14 weeks and provides a probability—not a diagnosis. For women who conceive after 35, first trimester screening for early pregnancy monitoring often includes a detailed discussion of these options.
Diagnostic Tests: What They Involve
Diagnostic tests provide definitive chromosomal information and are the only way to confirm or rule out chromosomal conditions with certainty. The two primary options are:
Chorionic Villus Sampling (CVS)
CVS involves sampling a small amount of placental tissue, typically performed between 10 and 13 weeks. Results can include a complete chromosomal picture. It carries a small procedural risk of pregnancy loss that varies by provider experience and facility, which is part of the decision-making conversation.
Amniocentesis
Amniocentesis is typically performed between 15 and 20 weeks and involves sampling amniotic fluid to analyze fetal chromosomes. It also carries a small procedural risk of pregnancy loss. Like CVS, it provides definitive chromosomal information rather than probability estimates.
Making Decisions About Testing
The decision about whether to pursue screening, diagnostic testing, both, or neither is profoundly personal. Some women want as much information as possible; others prefer to continue a pregnancy without detailed chromosomal information. Both approaches are valid, and the role of healthcare providers is to support informed decision-making rather than prescribe a single path.
Questions worth reflecting on before appointments include: What would I do with the information from a positive screen or diagnostic result? How do I feel about the procedural risks of diagnostic testing? What does my partner (if applicable) think about these options? A genetic counselor—a specialist in helping people understand and navigate genetic test options—can be an invaluable resource for working through these questions. Many practices offer genetic counseling as part of prenatal care.
Frequently Asked Questions
Is prenatal genetic testing mandatory after 35?
No. Testing is offered and discussed as an option, not required. ACOG guidelines emphasize informed patient choice. You have the right to decline testing, pursue only screening without diagnostic testing, or pursue the full spectrum of available options based on your values and circumstances.
What does a positive NIPT result mean?
A positive NIPT result indicates an elevated probability of a specific chromosomal condition, but it is not a diagnosis. ACOG recommends confirmatory diagnostic testing (CVS or amniocentesis) before making decisions based on a positive screening result. A genetic counselor can help you understand what a specific result means and what the next steps might be.
How soon will I get results?
Turnaround times vary by test and laboratory. NIPT results typically take 1-2 weeks, while first trimester combined screening may provide risk estimates more quickly since it incorporates ultrasound findings. Diagnostic test results from CVS or amniocentesis can take 1-3 weeks depending on the type of analysis requested.
Key Takeaways
- Prenatal genetic testing options include both screening tests (which assess probability) and diagnostic tests (which provide definitive chromosomal information)—understanding this distinction is essential.
- NIPT and first trimester combined screening are commonly offered screening options, while CVS and amniocentesis provide diagnostic certainty with small procedural risks.
- After 35, the statistical likelihood of certain chromosomal conditions increases with age, which is why testing conversations are more prominent—though most pregnancies in this age group are chromosomally typical.
- The decision to pursue genetic testing, which type, and how to respond to results is deeply personal; a genetic counselor can provide valuable support in navigating these choices.
- Testing is offered as an informed choice, not a requirement—your healthcare team should support your decision regardless of which path you choose.
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice. Individual health situations vary significantly. Always consult a qualified healthcare provider before making decisions related to your health, fertility, or pregnancy.
About the Author
Emily Carter is a women’s health writer focused on fertility, pregnancy after 35, and sleep changes in midlife. She writes research-informed, non-alarmist content to help women navigate reproductive and hormonal transitions with clarity and confidence.